Business Context and Reporting Period
Company: Viking Therapeutics, Inc. (Nasdaq: VKTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Viking is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. Key programs include VK2735 (obesity, Phase 3), VK2809 (NASH/MASH, Phase 2b), and VK0214 (X-ALD, Phase 1b). The company has no product revenue and relies on equity financing and interest income.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Revenues | $0 | $0 | $0 | $0 |
| Net Loss | $(128,022) | $(65,561) | $(286,347) | $(111,190) |
| Diluted EPS | $(1.10) | $(0.58) | $(2.47) | $(0.99) |
| Operating Expenses | $132,597 | $74,574 | $296,722 | $130,043 |
| Research & Development | $115,754 | $60,153 | $265,904 | $101,543 |
| General & Administrative | $16,843 | $14,421 | $30,818 | $28,500 |
| Cash & Equivalents | $125,750 | $165,810 | $125,750 | $165,810 |
| Short-term Investments | $375,913 | $539,929 | $375,913 | $539,929 |
| Total Liquidity | $501,663 | $705,739 | $501,663 | $705,739 |
| Operating Cash Flow (6M) | $(239,148) | $(99,392) | $(239,148) | $(99,392) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the six months ended June 30, 2026, increased by 158% compared to the same period in 2025, driven primarily by a 162% increase in R&D expenses.
- R&D Acceleration: R&D expenses rose from $101.5 million to $265.9 million (6M 2026 vs. 2025). This increase is attributed to the initiation and enrollment of Phase 3 VANQUISH-1 and VANQUISH-2 trials for VK2735, as well as Phase 2 oral dosing trials.
- Liquidity Reduction: Total cash, cash equivalents, and short-term investments decreased by approximately $204 million year-over-year due to higher operating cash burn, partially offset by financing activities.
- Financing Activity: The company raised $34.2 million net from an At-The-Market (ATM) offering during the first six months of 2026, compared to no ATM proceeds in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Cash Runway: Management believes current liquidity of approximately $502 million is sufficient to fund operations through at least September 30, 2027.
- Clinical Milestones: Patient enrollment for Phase 3 VANQUISH-1 and VANQUISH-2 (VK2735 subcutaneous) was completed in late 2025 and early 2026. Phase 3 oral dosing studies are expected to initiate in Q4 2026.
- Capital Needs: The company anticipates continued losses and expects to require additional capital to fund ongoing clinical trials and potential commercialization efforts.
Material Risks and Contingencies
- Ligand Pharmaceuticals Dispute: In April 2026, Ligand Pharmaceuticals notified Viking of a purported termination of the license for the TR-Beta Program (including VK2809 and VK0214). Ligand filed a complaint in May 2026; Viking filed a cross-complaint in July 2026 asserting the termination is invalid. A loss of these rights would materially harm the business.
- Trade Secret Litigation: Viking is engaged in ongoing litigation against Ascletis Defendants regarding trade secret misappropriation. The ITC ruled in Viking's favor in 2025, but the defendants have appealed to the Federal Circuit.
- Regulatory and Clinical Risk: As a clinical-stage company, Viking faces significant risks regarding the success of its clinical trials, regulatory approval, and the ability to commercialize products.
Unusual Items
- Stock Repurchase Program: In July 2026 (subsequent to period end), the Board terminated a $250 million repurchase program and authorized a new $500 million program.
- ATM Agreement Update: In July 2026, the company terminated its prior ATM agreement and entered into a new one with different agents.
- Executive Departure: The Chief Operating Officer, Marianne Mancini, announced her retirement effective July 31, 2026, with a transition to a consulting role.
Investor Verification Checklist
- Ligand Litigation Status: Verify the current status of the cross-complaint against Ligand Pharmaceuticals regarding the TR-Beta Program license termination.
- Cash Burn Rate: Monitor the quarterly cash burn rate to confirm the runway extends through late 2027 as projected.
- Phase 3 Enrollment: Confirm the timeline for data readouts from the VK2735 Phase 3 VANQUISH trials.
- Manufacturing Prepayments: Review the schedule and impact of prepayments to CordenPharma for dedicated manufacturing capacity.
- ATM Utilization: Track the utilization of the new $500 million stock repurchase program and the new ATM offering agreement.